ML
Therapeutic Areas
CytoMed Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CTM-N2D | Relapsed or refractory solid tumors (e.g., hepatocellular carcinoma, colorectal cancer) | Phase 1 |
| CAR-γδ T Cells | Hematological malignancies (e.g., Acute Myeloid Leukemia) | Pre-clinical |
Leadership Team at CytoMed Therapeutics
DT
Dr. Tan Wee Kiat
Chief Executive Officer
MJ
Mr. James G. B. M. Beh
Chief Operating Officer & Chief Financial Officer
DY
Dr. Yvonne Y. L. Yamanaka
Chief Medical Officer
DC
Dr. Chia Yoke Yin
Chief Scientific Officer
MA
Mr. Ang Peng Heong
Independent Director, Chairman of the Board
DF
Dr. Francois H. N. Lefebvre
Independent Director